Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04855591
Registration number
NCT04855591
Ethics application status
Date submitted
20/04/2021
Date registered
22/04/2021
Date last updated
1/12/2021
Titles & IDs
Public title
A Trial of SHR-1703 in Healthy Subjects
Query!
Scientific title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety, Tolerability, PK, PD and Immunogenicity of Single Subcutaneous Administered SHR-1703 in Healthy Caucasian Subjects
Query!
Secondary ID [1]
0
0
SHR-1703-104-AUS
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asthma
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - SHR-1703
Treatment: Drugs - Placebo
Experimental: SHR-1703 Dose Level 1 - Dose level 1 SHR-1703
Experimental: SHR-1703 Dose Level 2 - Dose level 2 SHR-1703
Experimental: SHR-1703 Dose Level 3 - Dose level 3 SHR-1703
Experimental: SHR-1703 Dose Level 4 (optional) - Dose level 4 SHR-1703 Additional dose escalations, as determined by the SMC depend on PK and safety data review
Treatment: Drugs: SHR-1703
SHR-1703 will be administered subcutaneously
Treatment: Drugs: Placebo
Placebo of SHR-1703 will be administered subcutaneously
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Adverse events
Query!
Assessment method [1]
0
0
Incidence and severity of adverse events
Query!
Timepoint [1]
0
0
Start of Treatment to end of study (approximately 34 weeks)
Query!
Secondary outcome [1]
0
0
Pharmacokinetics-AUC0-last
Query!
Assessment method [1]
0
0
Area under the concentration-time curve from time 0 to last time point after SHR-1703 administration
Query!
Timepoint [1]
0
0
Start of Treatment to end of study (approximately 34 weeks)
Query!
Secondary outcome [2]
0
0
Pharmacokinetics-AUC0-inf
Query!
Assessment method [2]
0
0
Area under the concentration-time curve from time 0 to infinity after SHR-1703 administration
Query!
Timepoint [2]
0
0
Start of Treatment to end of study (approximately 34 weeks)
Query!
Secondary outcome [3]
0
0
Pharmacokinetics-Tmax
Query!
Assessment method [3]
0
0
Time to Cmax of SHR-1703
Query!
Timepoint [3]
0
0
Start of Treatment to end of study (approximately 34 weeks)
Query!
Secondary outcome [4]
0
0
Pharmacokinetics-Cmax
Query!
Assessment method [4]
0
0
Maximum observed concentration of SHR-1703
Query!
Timepoint [4]
0
0
Start of Treatment to end of study (approximately 34 weeks)
Query!
Secondary outcome [5]
0
0
Pharmacokinetics-CL/F
Query!
Assessment method [5]
0
0
Apparent clearance of SHR-1703
Query!
Timepoint [5]
0
0
Start of Treatment to end of study (approximately 34 weeks)
Query!
Secondary outcome [6]
0
0
Pharmacokinetics-Vz/F
Query!
Assessment method [6]
0
0
Apparent volume of distribution during terminal phase of SHR-1703
Query!
Timepoint [6]
0
0
Start of Treatment to end of study (approximately 34 weeks)
Query!
Secondary outcome [7]
0
0
Pharmacokinetics-t1/2
Query!
Assessment method [7]
0
0
Terminal elimination half-life of SHR-1703
Query!
Timepoint [7]
0
0
Start of Treatment to end of study (approximately 34 weeks)
Query!
Secondary outcome [8]
0
0
Pharmacodynamics-Eosinophils
Query!
Assessment method [8]
0
0
Absolute eosinophils account and change from baseline in percentage
Query!
Timepoint [8]
0
0
Start of Treatment to end of study (approximately 34 weeks)
Query!
Secondary outcome [9]
0
0
Anti-drug-antibody
Query!
Assessment method [9]
0
0
The percentage of subjects with positive ADA titers over time for SHR-1703
Query!
Timepoint [9]
0
0
Start of Treatment to week 22 after IP administration
Query!
Eligibility
Key inclusion criteria
1. Healthy Caucasian subjects, male and female, 18 to 55 years of age, inclusive;
2. Body weight =45 kg (Both male and female), body mass index (BMI) between =19.0 and
=29.9 kg/m2, inclusive;
3. No clinically significant abnormalities in medical history, general physical
examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry
and coagulation function) and ECG at the investigator's discretion during screening
and baseline.
4. Men and women of childbearing potential (WOCBP) must agree to take effective
contraceptive methods and have no plan to have a child from signing the consent form
to 30-days after last scheduled follow-up visit.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. Known history or suspected of being allergic to the study drug.
2. Positive hepatitis B virus (HBsAg), hepatitis C virus (HCV-Ab), human immunodeficiency
virus (HIV-Ab) at screening.
3. Participation in clinical trials of other investigational drugs or medical devices
within 3 months prior to screening or within 5 half-lives of any drugs during
screening visit, or in the follow-up period of a clinical study whichever is longer
4. Use of any medicine within 4-weeks prior to the IP administration
5. Blood donation or loss of more than 400 mL of blood within 1 month of screening; or
received blood transfusion within 2 months before screening.
6. Live (attenuated) vaccination within 1 month before screening or plan to be vaccinated
7. Severe injuries or major surgeries within 6 months before screening or plan to do
surgeries during the trial
8. Patients with known or suspected parasitic infection within 6 months before screening
9. Either ALT, AST, ALP, GGT or total bilirubin level exceeds upper limit of normal range
(ULN) at screening or baseline visits (confirmed by a single repeat, as per
investigator's judgment)
10. More than 5 cigarettes daily (or products with equivalent amount of nicotine) for 3
months prior to screening.
11. History of alcohol abuse within 3 months prior to the IP administration
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
14/06/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
18/11/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
0
0
Nucleus Network - Brisbane
Query!
Recruitment postcode(s) [1]
0
0
- Brisbane
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Atridia Pty Ltd.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study.
The objective of this study is to evaluate the safety, tolerability, pharmacokinetics
pharmacodynamics and immunogenicity of subcutaneous administered SHR-1703 in healthy
subjects.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04855591
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Dr Richard Friend
Query!
Address
0
0
Nucleus Network
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04855591
Download to PDF